Novartis Ag

UniversitÉde Strasbourg

Institut National De La Sante Et De La Recherche Medicale

Novartis Pharma Gmbh

David Hicks

Jose-Alain Sahel

Saddek Mohand-Said

Thierry Leveillard

Thierry Léveillard

Olivier Poch

Thirry Léveillard

Carlos Alvarez

Jose Alain Sahel

Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.

Disease-associated proteins

Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed 'Rdcvf1,' that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.

Methods of treating retinitis pigmentosa using nucleic acids encoding RDCVF1 or RDCVF2

Compositions comprising polynucleotides encoding RDCVF1 or RDCVF2

Methods of increasing RDCVF 1 or RDCVF 2 polypeptides in retinal cells

Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed 'Rdcvf1,' that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.

Retinal dystrophy-associated protein and uses thereof

Polynucleotides encoding rod-derived cone viability factor (rdcvf) and methods of using the same

Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, chroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed 2Rdcvf1,' that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recongnize this protein, and methods for diagnosing such conditions.

Rod-derived cone viability factor (RDCVF) and a method of enhancing cone cell survival by RDCVF

Growing community of inventors

Strasbourg, France

David Hicks